# US 2012/0252039 A1 · Plasma kallikrein fragments as diagnostic biomarkers for lung cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252039 A1
- Document ID: US20120252039A1
- Status: Published application
- Kind: A1
- Application number: 13/494,215
- Filed: 2012-06-12
- Published: 2012-10-04
- Earliest claimed: 2007-03-21
- Assignees: Protan Bio Co., Ltd.
- Inventors: Je-Yeol CHO; Jae-Yong PARK; Seung-Jin LEE
- Web page: https://patentgrep.com/patent/US20120252039A1

## CPC

- G01N 33/5752: of the lungs
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment.

## Claims

### Claim 1

A method for diagnosing lung cancer in a subject, which comprises the steps of:
(a) bringing a biological sample into contact with an antibody binding specifically to the diagnostic marker of plasma kallikrein (KLKB1) fragment; and
(b) detecting the formation of an antigen-antibody complex.

### Claim 2 (depends on 1)

A method of claim 1, wherein the biological sample in the step (a) is serum.

### Claim 3 (depends on 1)

A method of claim 1, wherein the detection of the formation of the antigen-antibody in the step (b) is carried out using a method selected from the group consisting of RIA (radioimmunoassay), RIPA (radioimmunoprecipitation assay), IFA (immunofluorescence assay), ELISA (enzyme-linked immunosorbent assay) and Western blot.

### Claim 4

A method for diagnosing lung cancer, which comprises the steps of:
(a) removing a plasma kallikrein fragment and the heavy chain precursor form thereof from the serum of a subject;
(b) bringing the serum, from which the plasma kallikrein fragment and the heavy chain precursor form thereof had been removed in the step (a), into contact with an antibody specific for a region comprising the H4 domain of the plasma kallikrein fragment; and
(c) detecting the formation of an antigen-antibody complex.

### Claim 5 (depends on 4)

Method of claim 4, wherein the removal of the plasma kallikrein fragment or the heavy chain precursor form thereof in the step (a) is carried out by bringing the serum into contact with an antibody binding specifically to the plasma kallikrein fragment or is carried out using a molecular size separation column.

### Claim 6 (depends on 4)

Method of claim 4, wherein the detection of the antigen-antibody in the step (c) is carried out using a method selected from the group consisting of RIA (radioimmunoassay), RIPA (radioimmunoprecipitation assay), IFA (immunofluorescence assay), ELISA (enzyme-linked immunosorbent assay) and Western blot.

### Claim 7 (depends on 4)

Method of claim 4, wherein, if a fragment of 15-20 kDa is detected in the step (c), the subject is diagnosed to have lung cancer.
